CD123/CD33-LP-DNR

N/A

Report date: 2024/02/05 14:00:22

Base Information

Drug NameCD123/CD33-LP-DNR

Drug Alias NameCD123/CD33-LP-DNRCD123-CD33-LP-DNR

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Daunorubicin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionInterleukin-3 receptor subunit alpha inhibitorsMyeloid cell surface antigen CD33 inhibitors

TargetsMyeloid cell surface antigen CD33Interleukin-3 receptor subunit alpha

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSichuan University

China Registration ClassN/A

Develop Information

Active CompaniesSichuan University

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A